Andre Goy, MD, chairman, director, and chief of the Division of Lymphoma at John Theurer Cancer Center in Hackensack, NJ, discussed the potential benefits of using CAR T-cell therapies as a second-line treatment.
Andre Goy, MD, chairman, director, and chief of the Division of Lymphoma at John Theurer Cancer Center in Hackensack, NJ, discussed the potential benefits of using CAR T-cell therapies as a second-line treatment.
Transcript
After the approval of the first CAR T-cell therapies there was a discussion at ASCO about whether these therapies should be used earlier, when they might be more effective. What is the current thinking on this issue?
It is a very important aspect of CAR T-cell therapy because it is a game changer. And roughly 30-40% of patients have long-term benefits, particularly in aggressive lymphoma. That's sort of a main focus today. And what that means is that they're still 2 thirds of the patients who don't necessarily benefit or relapse after CAR T.
So, the question is how we can improve the concept of T-cell fitness and lessen the exposure to biochemotherapy for T-cells and the immune system. That seems to be very important. There're additional biomarkers, the inflammatory [garbled] prior to CAR T-cells that affects the response as well.
The next step is, because we've seen some activity in patients who have failed multiple lung therapy, can we actually take advantage of the CAR T-cell therapy earlier. To answer your question, there are ongoing trials that are looking at using CAR T, instead as a third line, like it is approved now, as a second line randomization versus an autologous stem cell transplant. All of these trials are being completed, like ZUMA-7. But there's also ongoing trials, that are looking at exactly the same question, to see if we can we actually improve the outcome of patients with larger lymphoma relapse, where we know with autologous stem cell transplantation, particularly in the early failure primary factory, has a very small percentage of long-term good outcome, using CAR T-cell therapy? So, there will be data at ASH's [American Society of Hematology] Annual Meeting. And some of these clinical trials are still ongoing, but it is very promising to try to bring a CAR T-cell earlier and improve the outcome in these patients.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More